-online.com Genomics

## Datasheet for ABIN5271479 Rat TXLNB CRISPR gRNA + Cas9 in Lenti Particles

## Overview

| Quantity:    | 300 µL   |
|--------------|--|
| Gene:        | Taxilin beta (TXLNB)   |
| Species:     | Rat  |
| Insert:      | gRNA + Cas9  |
| Vector:      | Lentiviral Vector  |
| Application: | Protein Expression (PExp), Genome Editing with Engineered Nucleases (GEEN) |

## Product Details

| Purpose:              | Individual gRNA against TxInb in Lentiviral Particles with a Titer of >1x10e7 IU/mL. (sgRNA and Cas9 in a single vector)  |
|-----------------------|---|
| Vector Backbone:      | pLenti-U6-sgRNA-SFFV-Cas9-2A-Puro   |
| Promoter:             | U6 Promoter, SFFV Promoter  |
| Selectable Marker:    | Puromycin   |
| Bacterial Resistance: | Ampicillin  |
| Expression Type:      | Stable, Transient   |
| Sequence:             | Sequence available upon placing order   |
| Specificity:          | GRNAs are designed for use with Cas9 Nuclease only.<br>Cas9 Nuclease is under the control of the SFFV promoter which should work for a vast majority<br>of cells, except ES cells or iPS cells. |
| Sequencing Primer:    | U6 Forward Primer: 5'TACGTCCAAGGTCGGGCAGGAAGA3'   |
| Components:           | Lentiviral particles with an individual gRNA (300 $\mu L)$ for a specific sequence of TxInb   |

| Target Details      |   |
|---------------------|---|
| Gene:               | Taxilin beta (TXLNB)  |
| Alternative Name:   | TxInb (TXLNB Products)  |
| NCBI Accession:     | NM_001135859  |
| Application Details |   |
| Application Notes:  | Recommended for quality control: Restriction Enzyme Digest and Sequencing                                 |
| Restrictions:       | For Research Use only   |
| Handling            |   |
| Format:             | Viral Particles   |
| Storage:            | -80 °C  |
| Expiry Date:        | 12 months   |
| Publications        |   |
| Product cited in:   | Johnson, Drugan, Miller, Evans: "38" in: , Vol. 1363, Issue Nucleic acids research, pp. 28-39, (<br>1991) |